Impact on loco-regional control of radiochemotherapeutic sequence and time to initiation of adjuvant treatment in stage II/III rectal cancer patients treated with postoperative concurrent radiochemotherapy

Haeyoung Kim, Eui Kyu Chie, Yong Chan Ahn, Kyubo Kim, Won Park, Won Sup Yoon, Seung Jae Huh, Sung W. Ha

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose This study was designed to evaluate the impact of radiochemotherapeutic sequence and time to initiation of adjuvant treatment on loco-regional control for resected stage II and III rectal cancer. Materials and Methods Treatment outcomes for rectal cancer patients from two hospitals with different sequencing strategies regarding adjuvant concurrent radiochemotherapy (CRCT) were compared retrospectively. Pelvic radiotherapy was administered concurrently on the first (early CRCT, n=180) or the third cycle of chemotherapy (late CRCT, n=180). During radiotherapy, two cycles of fluorouracil were provided to patients in both groups. In the early CRCT group, median six cycles of fluorouracil and leucovorin were prescribed during the post-CRCT period. In the late CRCT group, two cycles of fluorouracil were administered in the pre-and post-CRCT periods. Results No significant differences in the 5-year loco-regional recurrence-free survival (LRRFS) (92.5% vs. 95.6%, p=0.43) or overall survival and disease-free survival were observed between groups. Patients who began receiving adjuvant treatment later than five weeks after surgery had lower LRRFS than patients who received adjuvant treatment within five weeks following surgery (79% vs. 91%, p<0.01). The risk of loco-regional recurrence increased as the time to initiation of adjuvant treatment was delayed. Conclusion In the current study, treatment outcomes were not significantly influenced by the sequence of adjuvant treatment but by the delay of adjuvant treatment for more than five weeks. Timely administration of adjuvant treatment is deemed important in achieving loco-regional tumor control for stage II/III rectal cancer patients.

Original languageEnglish
Pages (from-to)148-157
Number of pages10
JournalCancer Research and Treatment
Volume46
Issue number2
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Chemoradiotherapy
Rectal Neoplasms
Fluorouracil
Recurrence
Therapeutics
Survival
Radiotherapy
Adjuvant Chemoradiotherapy
Leucovorin
Disease-Free Survival
Drug Therapy
Neoplasms

Keywords

  • Adjuvant chemoradiotherapy
  • Prognosis
  • Rectal neoplasms
  • Sequence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Impact on loco-regional control of radiochemotherapeutic sequence and time to initiation of adjuvant treatment in stage II/III rectal cancer patients treated with postoperative concurrent radiochemotherapy. / Kim, Haeyoung; Chie, Eui Kyu; Ahn, Yong Chan; Kim, Kyubo; Park, Won; Yoon, Won Sup; Huh, Seung Jae; Ha, Sung W.

In: Cancer Research and Treatment, Vol. 46, No. 2, 01.01.2014, p. 148-157.

Research output: Contribution to journalArticle

@article{cc2ed26868414158ab66af7c1313d28e,
title = "Impact on loco-regional control of radiochemotherapeutic sequence and time to initiation of adjuvant treatment in stage II/III rectal cancer patients treated with postoperative concurrent radiochemotherapy",
abstract = "Purpose This study was designed to evaluate the impact of radiochemotherapeutic sequence and time to initiation of adjuvant treatment on loco-regional control for resected stage II and III rectal cancer. Materials and Methods Treatment outcomes for rectal cancer patients from two hospitals with different sequencing strategies regarding adjuvant concurrent radiochemotherapy (CRCT) were compared retrospectively. Pelvic radiotherapy was administered concurrently on the first (early CRCT, n=180) or the third cycle of chemotherapy (late CRCT, n=180). During radiotherapy, two cycles of fluorouracil were provided to patients in both groups. In the early CRCT group, median six cycles of fluorouracil and leucovorin were prescribed during the post-CRCT period. In the late CRCT group, two cycles of fluorouracil were administered in the pre-and post-CRCT periods. Results No significant differences in the 5-year loco-regional recurrence-free survival (LRRFS) (92.5{\%} vs. 95.6{\%}, p=0.43) or overall survival and disease-free survival were observed between groups. Patients who began receiving adjuvant treatment later than five weeks after surgery had lower LRRFS than patients who received adjuvant treatment within five weeks following surgery (79{\%} vs. 91{\%}, p<0.01). The risk of loco-regional recurrence increased as the time to initiation of adjuvant treatment was delayed. Conclusion In the current study, treatment outcomes were not significantly influenced by the sequence of adjuvant treatment but by the delay of adjuvant treatment for more than five weeks. Timely administration of adjuvant treatment is deemed important in achieving loco-regional tumor control for stage II/III rectal cancer patients.",
keywords = "Adjuvant chemoradiotherapy, Prognosis, Rectal neoplasms, Sequence",
author = "Haeyoung Kim and Chie, {Eui Kyu} and Ahn, {Yong Chan} and Kyubo Kim and Won Park and Yoon, {Won Sup} and Huh, {Seung Jae} and Ha, {Sung W.}",
year = "2014",
month = "1",
day = "1",
doi = "10.4143/crt.2014.46.2.148",
language = "English",
volume = "46",
pages = "148--157",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Society for Thoracic and Cardiovascular Surgery",
number = "2",

}

TY - JOUR

T1 - Impact on loco-regional control of radiochemotherapeutic sequence and time to initiation of adjuvant treatment in stage II/III rectal cancer patients treated with postoperative concurrent radiochemotherapy

AU - Kim, Haeyoung

AU - Chie, Eui Kyu

AU - Ahn, Yong Chan

AU - Kim, Kyubo

AU - Park, Won

AU - Yoon, Won Sup

AU - Huh, Seung Jae

AU - Ha, Sung W.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose This study was designed to evaluate the impact of radiochemotherapeutic sequence and time to initiation of adjuvant treatment on loco-regional control for resected stage II and III rectal cancer. Materials and Methods Treatment outcomes for rectal cancer patients from two hospitals with different sequencing strategies regarding adjuvant concurrent radiochemotherapy (CRCT) were compared retrospectively. Pelvic radiotherapy was administered concurrently on the first (early CRCT, n=180) or the third cycle of chemotherapy (late CRCT, n=180). During radiotherapy, two cycles of fluorouracil were provided to patients in both groups. In the early CRCT group, median six cycles of fluorouracil and leucovorin were prescribed during the post-CRCT period. In the late CRCT group, two cycles of fluorouracil were administered in the pre-and post-CRCT periods. Results No significant differences in the 5-year loco-regional recurrence-free survival (LRRFS) (92.5% vs. 95.6%, p=0.43) or overall survival and disease-free survival were observed between groups. Patients who began receiving adjuvant treatment later than five weeks after surgery had lower LRRFS than patients who received adjuvant treatment within five weeks following surgery (79% vs. 91%, p<0.01). The risk of loco-regional recurrence increased as the time to initiation of adjuvant treatment was delayed. Conclusion In the current study, treatment outcomes were not significantly influenced by the sequence of adjuvant treatment but by the delay of adjuvant treatment for more than five weeks. Timely administration of adjuvant treatment is deemed important in achieving loco-regional tumor control for stage II/III rectal cancer patients.

AB - Purpose This study was designed to evaluate the impact of radiochemotherapeutic sequence and time to initiation of adjuvant treatment on loco-regional control for resected stage II and III rectal cancer. Materials and Methods Treatment outcomes for rectal cancer patients from two hospitals with different sequencing strategies regarding adjuvant concurrent radiochemotherapy (CRCT) were compared retrospectively. Pelvic radiotherapy was administered concurrently on the first (early CRCT, n=180) or the third cycle of chemotherapy (late CRCT, n=180). During radiotherapy, two cycles of fluorouracil were provided to patients in both groups. In the early CRCT group, median six cycles of fluorouracil and leucovorin were prescribed during the post-CRCT period. In the late CRCT group, two cycles of fluorouracil were administered in the pre-and post-CRCT periods. Results No significant differences in the 5-year loco-regional recurrence-free survival (LRRFS) (92.5% vs. 95.6%, p=0.43) or overall survival and disease-free survival were observed between groups. Patients who began receiving adjuvant treatment later than five weeks after surgery had lower LRRFS than patients who received adjuvant treatment within five weeks following surgery (79% vs. 91%, p<0.01). The risk of loco-regional recurrence increased as the time to initiation of adjuvant treatment was delayed. Conclusion In the current study, treatment outcomes were not significantly influenced by the sequence of adjuvant treatment but by the delay of adjuvant treatment for more than five weeks. Timely administration of adjuvant treatment is deemed important in achieving loco-regional tumor control for stage II/III rectal cancer patients.

KW - Adjuvant chemoradiotherapy

KW - Prognosis

KW - Rectal neoplasms

KW - Sequence

UR - http://www.scopus.com/inward/record.url?scp=84900427017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900427017&partnerID=8YFLogxK

U2 - 10.4143/crt.2014.46.2.148

DO - 10.4143/crt.2014.46.2.148

M3 - Article

VL - 46

SP - 148

EP - 157

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 2

ER -